Drug Development


Psilocybin Clinical Trial Phases | Usona Institute is between phase 2 and 3

Completed Psilocybin Clinical Trials


This is the largest Phase 2, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of a single dose of psilocybin to treat major depressive disorder. Psilocybin treatment was administered with psychosocial support, prioritizing optimal set and setting for study participants.

The results from PSIL201 can be viewed here.


This is a phase 1, two-part study evaluating two important clinical pharmacology questions:

1) Does psilocybin have the potential to delay cardiac repolarization (i.e., prolong the QT interval)?

2) Does consuming a meal prior to administration of psilocybin affect drug absorption?

Clinical conduct of PSIL102 is complete, and the study is closed to enrollment. We are currently analyzing the data from this study and plan to share the results in a future publication.

To learn more about the study please visit www.clinicaltrials.gov.

Breakthrough Therapy Designation

The FDA describes Breakthrough Therapy designation as “a process designed to expedite the development and review of drugs that are intended to treat a serious condition and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over available therapy on a clinically significant endpoint(s).“ In 2019, the FDA granted Breakthrough Therapy designation to Usona’s Investigational New Drug application for psilocybin as a potential treatment for major depressive disorder.

Expanded Access Policy

We do not offer expanded access at this time.